Allspring Global Investments Holdings LLC Sells 251 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

Allspring Global Investments Holdings LLC lessened its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 6.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,378 shares of the company’s stock after selling 251 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Apogee Therapeutics were worth $198,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of APGE. Arizona State Retirement System raised its stake in shares of Apogee Therapeutics by 4.5% in the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock worth $236,000 after purchasing an additional 258 shares during the last quarter. EntryPoint Capital LLC raised its position in Apogee Therapeutics by 44.7% during the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock worth $133,000 after acquiring an additional 617 shares during the period. Principal Financial Group Inc. increased its stake in Apogee Therapeutics by 26.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock worth $253,000 after buying an additional 1,340 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in Apogee Therapeutics by 25.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock valued at $517,000 after purchasing an additional 1,800 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its stake in Apogee Therapeutics by 111.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company’s stock valued at $274,000 after acquiring an additional 2,172 shares in the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Analyst Ratings Changes

Separately, Wedbush reaffirmed an “outperform” rating and set a $87.00 target price on shares of Apogee Therapeutics in a research note on Friday, October 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Apogee Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $78.50.

Apogee Therapeutics Stock Performance

Shares of APGE opened at $54.49 on Monday. The company’s 50-day simple moving average is $53.28 and its 200-day simple moving average is $48.45. The stock has a market capitalization of $2.45 billion, a PE ratio of -26.32 and a beta of 2.94. Apogee Therapeutics, Inc. has a 1 year low of $14.19 and a 1 year high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.60). On average, sell-side analysts predict that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Insider Activity

In related news, CFO Jane Henderson sold 6,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $48.26, for a total transaction of $289,560.00. Following the completion of the transaction, the chief financial officer now owns 200,871 shares in the company, valued at approximately $9,694,034.46. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Michael Thomas Henderson sold 40,000 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $40.62, for a total value of $1,624,800.00. Following the transaction, the chief executive officer now directly owns 1,434,487 shares of the company’s stock, valued at $58,268,861.94. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Jane Henderson sold 6,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $48.26, for a total transaction of $289,560.00. Following the completion of the sale, the chief financial officer now directly owns 200,871 shares of the company’s stock, valued at approximately $9,694,034.46. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 146,665 shares of company stock worth $7,058,635. 36.10% of the stock is currently owned by corporate insiders.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.